Phosphorylation of threonine 333 regulates trafficking of the human sst5 somatostatin receptor

Molecular Endocrinology

Volumn 27, Issue 4, 2013, Pages 671-682

  Petrich, Aline ^a   Mann, Anika ^a   Kliewer, Andrea ^a   Nagel, Falko ^a   Strigli, Anne ^a   Märtens, Jan Carlo ^a   Pöll, Florian ^a   Schulz, Stefan ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BIM 23268; CALYCULIN A; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; OCTREOTIDE; OKADAIC ACID; PASIREOTIDE; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN KINASE C; SERINE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 5; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CONTROLLED STUDY; DEGLYCOSYLATION; DEPHOSPHORYLATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; BIOCATALYSIS; ENDOCYTOSIS; G-PROTEIN-COUPLED RECEPTOR KINASE 2; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; OXAZOLES; PHOSPHORYLATION; PHOSPHOTHREONINE; PROTEIN PHOSPHATASE 1; PROTEIN TRANSPORT; RECEPTORS, SOMATOSTATIN;

EID: 84875541584     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1329     Document Type: Article

References (28)

1. Weckbecker G, Lewis I, Albert R, Schmid H.A., Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2:999-1017.
2. Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21:123-133.
3. Colao A, Auriemma R.S., Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2012;32:247- 271.
4. Plockinger U, Albrecht S, Mawrin C, et al. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. J Clin Endocrinol Metab. 2008;93:1203-1210.
5. Lewis I, Bauer W, Albert R, et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003;46:2334-2344.
6. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707-716.
7. Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2011;366: 914-924.
8. Oberg K.E., Reubi J.C., Kwekkeboom D.J., Krenning E.P. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139:742-753, 753 e741.
9. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2009;95:2781-2789.
10. Kliewer A, Mann A, Petrich A, Poll F, Schulz S. A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation. PLoS One. 2012;7:e39458.
11. Nagel F, Doll C, Poll F, Kliewer A, Schroder H, Schulz S. Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor. Mol Endocrinol. 2011;25:859-866.
12. Poll F, Lehmann D, Illing S, et al. Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol. 2010;24:436-446.
13. Tulipano G, Stumm R, Pfeiffer M, Kreienkamp H.J., Hollt V, Schulz S. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem. 2004;279:21374- 21382.
14. Poll F, Doll C, Schulz S. Rapid dephosphorylation of G proteincoupled receptors by protein phosphatase 1beta is required for termination of beta-arrestin-dependent signaling. J Biol Chem. 2011; 286:32931-32936.
15. Hukovic N, Panetta R, Kumar U, Rocheville M, Patel Y.C. The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylyl cyclase and in mediating desensitization and internalization. J Biol Chem. 1998;273:21416-21422.
16. Peverelli E, Mantovani G, Calebiro D, et al. The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation. Mol Endocrinol. 2008;22:676-688.
17. Lupp A, Hunder A, Petrich A, Nagel F, Doll C, Schulz S. Reassessment of sst(5) somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4. Neuroendocrinology. 2011;94:255-264.
18. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab. 2008;93:4519-4524.
19. Pfeiffer M, Koch T, Schroder H, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem. 2001; 276:14027-14036.
20. Schulz S, Mayer D, Pfeiffer M, Stumm R, Koch T, Hollt V. Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J. 2004;23:3282- 3289.
21. Schulz S, Pauli S.U., Schulz S, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000;6:1865-1874.
22. Lesche S, Lehmann D, Nagel F, Schmid H.A., Schulz S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab. 2009; 94:654-661.
23. Honkanen R.E., Golden T. Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr Med Chem. 2002; 9:2055-2075.
24. Hanyaloglu A.C., Zastrow M.V. Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol. 2008;48:537-568.
25. Doll C, Konietzko J, Poll F, Koch T, Hollt V, Schulz S. Agonistselective patterns of μ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol. 2011;164:298- 307.
26. Doll C, Poll F, Peuker K, Loktev A, Gluck L, Schulz S. Deciphering μ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br J Pharmacol. 2012;167:1259-1270.
27. Asnacios A, Courbon F, Rochaix P, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol. 2008;26:963-970.
28. Sharif N, Gendron L, Wowchuk J, et al. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology. 2007;148:2095-2105.